TCHHL1 Inhibitors
Chemical inhibitors of TCHHL1 function by targeting cell cycle regulatory mechanisms, predominantly through the inhibition of cyclin-dependent kinases (CDKs), which are enzymes critical for the progression of the cell cycle and thus for keratinocyte differentiation. Alsterpaullone, Kenpaullone, Indirubin-3'-monoxime, Roscovitine, Olomoucine, Purvalanol A, Flavopiridol, PD0332991, Milciclib, SNS-032, Ribociclib, and Abemaciclib all share a common mechanism of CDK inhibition, albeit with varying specificities and potencies towards different CDKs. For example, Alsterpaullone and Kenpaullone are known for their ability to inhibit CDKs, which can lead to an arrest in the cell cycle. This arrest can impede the normal function of TCHHL1 in keratinocyte differentiation, as the differentiation process is tightly linked to the cell cycle. Indirubin-3'-monoxime extends its inhibition to glycogen synthase kinase 3 (GSK-3), another kinase involved in cell regulation, which could further influence the role of TCHHL1 in skin cell proliferation and differentiation.
In the second paragraph of description, compounds like Roscovitine, Olomoucine, and Flavopiridol selectively target various CDKs, which can disrupt the cell cycle at specific phases, thereby impacting TCHHL1 function in the epidermal development. The more targeted inhibitors, such as PD0332991 (Palbociclib), Ribociclib, and Abemaciclib, specifically inhibit CDK4/6, key players in the G1 to S phase transition, which can result in cell cycle arrest. This focused action can lead to a pronounced disruption of the cell cycle-dependent functions of TCHHL1. Furthermore, Milciclib, though a CDK inhibitor, might affect TCHHL1 function by a similar cell cycle arrest mechanism. Lastly, SNS-032, with its potent inhibition of CDK2, 7, and 9, can halt the cell cycle machinery necessary for keratinocyte differentiation, thereby influencing the functional role of TCHHL1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs), and since TCHHL1 is involved in keratinocyte differentiation, inhibiting CDKs could disrupt the cell cycle and thus the function of TCHHL1 in this differentiation pathway. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $60.00 $150.00 $226.00 $495.00 | 1 | |
Kenpaullone is another CDK inhibitor which can interfere with the cell cycle. By altering the cell cycle, the cellular differentiation processes involving TCHHL1 can be inhibited. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
This molecule inhibits CDKs and glycogen synthase kinase 3 (GSK-3), potentially disrupting processes that are necessary for the function of TCHHL1 in skin cell proliferation and differentiation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine selectively inhibits CDKs. Since TCHHL1 has a role in epidermal development and differentiation, inhibition of CDKs can lead to an inhibition of TCHHL1 function by disrupting the necessary cell cycle progression. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Targeting CDKs, Olomoucine can impede the cell cycle, potentially leading to an inhibition of TCHHL1 since its function is tied to the differentiation of keratinocytes, which is a cell cycle-dependent process. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is another inhibitor of CDKs that can disrupt the cell cycle progression, and consequently, the regulated function of TCHHL1 in the epidermal differentiation process can be inhibited. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol strongly inhibits various CDKs and can inhibit TCHHL1 function by disrupting the cell cycle and, therefore, keratinocyte differentiation where TCHHL1 is involved. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Also known as Palbociclib, this inhibits CDK4/6 and could lead to an inhibition of TCHHL1 function by arresting the cell cycle which is necessary for keratinocyte differentiation where TCHHL1 is implicated. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib, a CDK inhibitor, can interfere with the cell cycle, potentially leading to inhibition of TCHHL1, which is involved in the process of skin cell differentiation that relies on proper cell cycle progression. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a potent inhibitor of CDKs, mainly CDK2, 7, and 9, and can inhibit TCHHL1 functionality indirectly by interrupting cell cycle-dependent processes such as keratinocyte differentiation. | ||||||